# LRMR catalysts: Larimar Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/lrmr/catalysts

> Larimar Therapeutics, Inc. (LRMR) has 4 upcoming catalysts. The next is the nomlabofusp primary completion, January 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Larimar Therapeutics, Inc. |
| Ticker | LRMR (Nasdaq) |
| SEC CIK | 1374690 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/lrmr |

## Cash runway

Cash $156.3M as of 2026-06-30; quarterly burn $44.0M; about 10.6 months of runway at that rate (XBRL company facts, accession 0001193125-26-331529).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2024 | [Nomlabofusp trial start](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | completed | "In January 2024, we initiated the OL trial evaluating daily SC injections of 25 mg of nomlabofusp self-administered or administered by a caregiver, with the first patient dosed in March 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1374690/000119312526115878/lrmr-20251231.htm)) |
| Feb 2024 | [Nomlabofusp topline data readout](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | completed, positive | "In February 2024, the Company reported positive top-line data and successful completion of the Phase 2 dose exploration study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1374690/000095017025061222/lrmr-20250331.htm)) |
| December 16, 2024 | [Nomlabofusp interim data readout](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | completed, positive | "Bala Cynwyd, PA, December 16, 2024 - Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with FA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000095017024136384/lrmr-ex99_1.htm)) |
| March 24, 2025 | [Nomlabofusp earnings report](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | completed | "Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000095017025043487/lrmr-ex99_1.htm)) |
| March 31, 2025 | [Nomlabofusp trial start](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | completed | "The increase was primarily driven by an increase of $7.1 million in nomlabofusp manufacturing costs, an increase of $2.8 million in clinical costs primarily associated with the ongoing pediatric study which started and completed patient enrollment in the quarter ended March 31, 2025 and the start of our planned global Phase 3 study in the first quarter of 2025, an increase of $1.6 million in personnel expense due to increased headcount, and an increase of $1.2 million in consulting fees." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1374690/000095017025061222/lrmr-20250331.htm)) |
| mid-2025 | [Nomlabofusp trial start](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | scheduled | "In mid-2025 we expect to initiate our global Phase 3 study following global regulatory feedback on the study protocol, and we also expect to transition to the lyophilized formulation of nomlabofusp." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000095017025060563/lrmr-ex99_1.htm)) |
| April 30, 2025 | [Larimar Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lrmr/catalysts) | LRMR |  | completed | "Larimar Therapeutics Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000095017025060563/lrmr-ex99_1.htm)) |
| August 14, 2025 | [Larimar Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lrmr/catalysts) | LRMR |  | completed | "Larimar Therapeutics Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000095017025108409/lrmr-ex99_1.htm)) |
| August 19, 2025 | [SKYCLARYS® (omaveloxolone) PDUFA date](https://sec-api.dev/pdufa/omaveloxolone) | LRMR | children and adults living with FA | scheduled | "The FDA has accepted for filing PTC's NDA for vatiquinone for the treatment of children and adults living with FA with a target action date of August 19, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1374690/000095017025043925/lrmr-20241231.htm)) |
| Sep 2025 | [Nomlabofusp topline data readout](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | scheduled | "Completed dosing in adolescent PK run-in study; topline 50 mg dose data from the OLE study and data from adolescent cohort planned for program update in September 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000095017025060563/lrmr-ex99_1.htm)) |
| Sep 2025 | [Nomlabofusp interim data readout](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | scheduled | "We have several important near-term catalysts ahead including initial data from the 50 mg dose of our open label study and data from the adolescent pharmacokinetic (PK) run-in study expected in September 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000095017025108409/lrmr-ex99_1.htm)) |
| Q4 2025 | [Nomlabofusp NDA/BLA submission](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | scheduled | "Process performance qualification (PPQ) on the commercial scale drug substance is planned in the fourth quarter of 2025, in preparation of data for BLA submission." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000119312525265702/lrmr-ex99_1.htm)) |
| November 5, 2025 | [Larimar Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lrmr/catalysts) | LRMR |  | completed | "Larimar Therapeutics Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000119312525265702/lrmr-ex99_1.htm)) |
| March 19, 2026 | [Larimar Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lrmr/catalysts) | LRMR |  | completed | "Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000119312526115119/lrmr-ex99_1.htm)) |
| Q2 2026 | [Larimar Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/lrmr/catalysts) | LRMR |  | scheduled | "We plan to provide topline study data from our OL study in the second quarter of 2026 and we plan to initiate a rolling BLA seeking accelerated approval with the submission of nonclinical and clinical modules in June 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1374690/000119312526224087/lrmr-20260331.htm)) |
| Q2 2026 | [Nomlabofusp topline data readout](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | scheduled | "Topline OL Study Data in Second Quarter of 2026: Larimar plans to report topline data from the OL study that is intended to support BLA submission in the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000119312526222746/lrmr-ex99_1.htm)) |
| May 14, 2026 | [Larimar Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lrmr/catalysts) | LRMR |  | completed | "Bala Cynwyd, PA, May 14, 2026 - Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2026 operating and financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000119312526222746/lrmr-ex99_1.htm)) |
| Jun 2026 | [Nomlabofusp trial start](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | scheduled | "We continue to plan for a June 2026 BLA submission seeking accelerated approval and are excited to initiate our confirmatory Phase 3 study in the U.S., E.U., U.K., Canada and Australia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000119312526065186/lrmr-ex99_1.htm)) |
| June 29, 2026 | [Nomlabofusp NDA/BLA submission](https://sec-api.dev/pdufa/nomlabofusp) | LRMR | broad population of patients | completed | "On June 29, 2026, Larimar Therapeutics, Inc. (the "Company") issued a press release announcing (i) that it has submitted the first module of the Company's rolling Biologics License Application submission to the Food and Drug Administration for accelerated approval of nomlabofusp and (ii) positive data from the Company's ongoing long-term open label study evaluating daily subcutaneous injections of nomlabofusp in adolescent and adult patients with Friedreich's ataxia." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1374690/000119312526286780/lrmr-20260629.htm)) |
| 2H 2026 | [Nomlabofusp NDA/BLA acceptance](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | scheduled | "We initiated our rolling BLA submission to the FDA for marketing approval of nomlabofusp using the accelerated approval pathway and expect to submit the remaining modules in the second half of 2026; however, there can be no assurance that we will submit the remaining modules on our expected timeline, that the FDA will accept the BLA for filing or the FDA will approve our BLA submission for accelerated approval." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1374690/000119312526331529/lrmr-20260630.htm)) |
| 2H 2026 | [Nomlabofusp NDA/BLA submission](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | scheduled | "To facilitate a seamless review process, we continue to focus on the completeness of our chemistry, manufacturing, and controls (CMC) module, and plan to submit the CMC portion of the BLA in the second half of 2026," said Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000119312526222746/lrmr-ex99_1.htm)) |
| August 4, 2026 | [Larimar Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lrmr/catalysts) | LRMR |  | completed | "Bala Cynwyd, PA, August 4, 2026 - Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter 2026 operating and financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/lrmr-ex99_1.htm)) |
| January 2027 | [Nomlabofusp primary completion](https://sec-api.dev/pdufa/nomlabofusp) | LRMR | Friedreich Ataxia | scheduled | "NCT06447025 (An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Larimar Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06447025)) |
| Jan to Apr 2027 | [Nomlabofusp topline data readout](https://sec-api.dev/pdufa/nomlabofusp) | LRMR | Friedreich Ataxia | scheduled | "NCT06447025 (An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Larimar Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06447025)) |
| July 2029 | [Nomlabofusp primary completion](https://sec-api.dev/pdufa/nomlabofusp) | LRMR | Friedreich Ataxia; Friedreich's Ataxia | scheduled | "NCT07778836 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Larimar Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07778836)) |
| Jul to Oct 2029 | [Nomlabofusp topline data readout](https://sec-api.dev/pdufa/nomlabofusp) | LRMR | Friedreich Ataxia; Friedreich's Ataxia | scheduled | "NCT07778836 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Larimar Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07778836)) |

## Drugs

- [Nomlabofusp](https://sec-api.dev/pdufa/nomlabofusp): broad population of patients, Friedreich Ataxia

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/lrmr/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LRMR catalysts: Larimar Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/lrmr/catalysts

```bibtex
@misc{secapidev_companies_lrmr_catalysts_20261116,
  title        = {LRMR catalysts: Larimar Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/lrmr/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_lrmr_catalysts_20261116","title":"LRMR catalysts: Larimar Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/lrmr/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
